Stockscreener 앱 받기
43.42
2.70%
1.14
Nektar Therapeutics 주식(NKTR)의 최신 뉴스
Nektar Therapeutics: Can a Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS
How Nektar Therapeutics stock reacts to global recession fearsGrowth vs. Value Investing & Optimize Entry & Exit With Smart Signals - bollywoodhelpline.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar TherapeuticsNKTR - PR Newswire
Drugs to Watch in 2026 - Dermatology Times
Nektar Therapeutics Stock Analysis and ForecastStock Screening Results & Outstanding Return Portfolio - earlytimes.in
Moody Aldrich Partners LLC Buys 28,304 Shares of Nektar Therapeutics $NKTR - MarketBeat
Top 10 skin disorder stories of 2025 - Healio
Simplify Asset Management Inc. Buys 35,176 Shares of Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Wrap: Why Nektar Therapeutics stock could rally in 2025Earnings Growth Summary & Risk Adjusted Buy/Sell Alerts - moha.gov.vn
Dermatology Times 2025 Year in Review: Atopic Dermatitis - Dermatology Times
Nektar Therapeutics Shares Rise After Positive Asthma Data in Atopic Dermatitis Patients - MSN
Brain Implants for Mental Health and Chinese Competition Expected to Shape BCI Advancements by 2026 - geneonline.com
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Nektar Therapeutics (NKTR) price target increased by 14.31% to 109.43 - MSN
More Unpleasant Surprises Could Be In Store For Nektar Therapeutics' (NASDAQ:NKTR) Shares After Tumbling 25% - simplywall.st
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Nektar Therapeutics (NKTR) CEO reports RSU and stock option grants - Stock Titan
Will Nektar Therapeutics (ITH0) stock outperform energy sector in 2025Earnings Miss Alerts & Maximize ROI With Proven Growth Stocks - Bollywood Helpline
Published on: 2025-12-23 18:23:01 - moha.gov.vn
Nektar Therapeutics announces phase 2b trial results - MSN
Atopic Dermatitis in 2025: Year in Review - HCPLive
Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data - Benzinga
Transformative Advances This Year and Beyond - Dermatology Times
Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) - Insider Monkey
Is Nektar Therapeutics (ITH0) stock ideal for retirement investors2025 Trading Volume Trends & Accurate Buy Signal Alerts - ulpravda.ru
Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions - Seeking Alpha
Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows - Yahoo Finance
Machine Learning Tool vConTACT3 Developed to Enhance Global Virus Classification - geneonline.com
Is Nektar Therapeutics stock resilient to inflationMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - Улправда
Why analysts remain bullish on Nektar Therapeutics stockMarket Rally & Reliable Price Breakout Signals - DonanımHaber
Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation - MSN
Assessing Nektar Therapeutics (NKTR) Valuation After a Volatile Year and Recent Share Price Pullback - simplywall.st
Nektar Therapeutics Q3 2025 Earnings Preview - MSN
Oppenheimer maintains Outperform rating on Q32 Bio stock at $20 target - Investing.com
Nektar Therapeutics announces top-line results from alopecia areata study - PMLiVE
Nektar Therapeutics Price Target Raised to $118.00/Share From $100.00 by BTIG - 富途牛牛
Nektar Therapeutics Is Maintained at Buy by BTIG - 富途牛牛
Nektar Therapeutics stock price target raised to $135 at H.C. Wainwright on alopecia data - Investing.com Nigeria
Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg (NASDAQ:NKTR) - Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 6.5%Should You Sell? - MarketBeat
Rezpegaldesleukin Demonstrates Proof of Concept in Phase 2b Trial for Severe Alopecia Areata - Patient Care Online
Jefferies Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $121 - news.futunn.com
Nektar Therapeutics to Advance Rezpeg into Phase III Trials for Alopecia Areata Despite Phase II Endpoint Miss - geneonline.com
Nektar Therapeutics Earnings Notes - Trefis
BTIG Research Issues Positive Forecast for Nektar Therapeutics (NASDAQ:NKTR) Stock Price - MarketBeat
REZOLVE-AA: Phase 2b Data Released on Rezpegaldesleukin for Alopecia Areata - HCPLive
Nektar Digs Into Mid-Stage Data to Establish Alopecia Efficacy of Rezpeg - BioSpace
Nektar reports positive Ph IIb results in alopecia areata - The Pharma Letter
Promising Efficacy and Safety of Rezpegaldesleukin Positions Nektar Therapeutics as a Leader in Alopecia Areata Treatment - TipRanks
BTIG Maintains Nektar Therapeutics (NKTR) Buy Recommendation - Nasdaq
Nektar Therapeutics (NKTR) PT Raised to $135 at H.C. Wainwright - StreetInsider
Nektar Blames Eligibility Violations For Phase II Rezpeg Miss, Backs Alopecia Development Plans - Citeline News & Insights
Jefferies reiterates Buy rating on Nektar Therapeutics stock with $121 price target - Investing.com Australia
Jefferies Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
0.57%
자본화:
|
볼륨(24시간):